Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Blopress Keeps Top Place 5 Years in a Row
July 6, 2009
- New GL on COPD to Recommend β2 Stimulant + Inhaled Steroid Combinations
July 6, 2009
- FY2008 Sales of Ethical Drugs Up 2.9% to ¥8,368.6 Bil.: IMS Japan
July 6, 2009
- JSMI Introduces New Voluntary GL for Ad of OTC Drugs
July 6, 2009
- BUSINESS NEWS IN BRIEF
July 6, 2009
- Tamiflu Is Not Ineffective against Resistant Viruses
June 29, 2009
- BUSINESS NEWS IN BRIEF
June 29, 2009
- Pandemic of New-Type Flu Infections Unavoidable in Japan in Oct-Nov: Prof. Oshitani
June 29, 2009
- TOPICS 2 articles
June 29, 2009
- Memantine Dosage Titration Necessary in Patients with Renal Disorders
June 29, 2009
- Zithromac Leaps to Top Place in April: Rep Track Survey
June 29, 2009
- Expert Committee Recommends HbA1C for Diagnosis of Diabetes
June 29, 2009
- Distribution Business Reform in FY2008 Was Failure: Mr Matsutani
June 29, 2009
- R&D NEWS IN BRIEF
June 29, 2009
- Injectable Risperdal to Change Treatment of Schizophrenia: Janssen
June 29, 2009
- Japan Participates in Multinational PIII Study of JAK-3 Inhibitor: Pfizer
June 29, 2009
- Eli Lilly Japan to Increase Sales of Anticancer Drugs to 30% of Total Sales
June 29, 2009
- Top Quark to Create New CRO to Undertake Asian Trials
June 29, 2009
- Glufast, Urief to Drive Kissei's Growth: Dr Ajisawa
June 29, 2009
- Asahi Kasei Medical: Planova BioEX
June 29, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…